Drugs / rhIGF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00764699 | Oct 2008 → May 2010 | Crohn disease | Nationwide Children's Hospital | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhIGF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00764699 ↗ |
| Known as | Increlex | “Increlex (rhIGF)” NCT00764699 ↗ |
| Action | Restore | “replacement of IGF-1 with rhIGF will correct growth” NCT00764699 ↗ |
| Modality | Protein / enzyme biologic | “recombinant IGF-1 (rhIGF)” NCT00764699 ↗ |
| Route | Subcutaneous | “rhIGF will be administered as a subcutaneous injection” NCT00764699 ↗ |